Article date: December 2016
By: Seyed Hamidreza Mahmoudpour, Ekaterina Vitalievna Baranova, Patrick C. Souverein, Folkert W. Asselbergs, Anthonius Boer, Anke Hilse Maitland‐van der Zee, on behalf of the PREDICTION‐ADR consortium, on behalf of the PREDICTION‐ADR consortium in Volume 82, Issue 6, pages 1647-1659
Aim
The aim of the present study was to describe the occurrence and determinants of angiotensin‐converting enzyme (ACE) inhibitor (ACEI) intolerance and angioedema (AE) among patients initiating ACEI therapy in a real‐world primary care population.
Methods
Two nested case–control studies were conducted in a cohort of 276 977 patients aged ≥45 years initiating ACEIs from 2007 to 2014 in the UK Clinical Practice Research Datalink (CPRD). Cases of AE occurring for the first time during ACEI therapy (n = 416) were matched with AE‐free controls (n = 4335) on the duration of ACEI treatment. Documented switches to angiotensin‐II receptor blockers in the prescription records were used to identify ACEI‐intolerance cases (n = 24 709), and these were matched with continuous ACEI users (n = 84 238) on the duration of ACEI therapy. Conditional logistic regression was used to assess the associations of demographic factors, comorbidities and comedication with AE and ACEI intolerance.
Results
AE during ACEI therapy was associated with age over 65 years [odds ratio (OR) 1.36, 95% confidence interval (CI) 1.07, 1.73], history of allergy (OR 1.53, 95% CI 1.19, 1.96), use of calcium channel blockers (OR 1.57, 95% CI 1.23; 2.01), use of antihistamines (OR 21.25, 95% CI 16.44, 27.46) and use of systemic corticosteroids (OR 4.52, 95% CI 3.26, 6.27). ACEI intolerance was significantly associated with more comorbidities and comedication compared with AE, including allergy (OR 2.02, 95% CI 1.96, 2.09), use of antiasthmatic drugs (OR 1.51, 95% CI 1.42, 1.61) and use of antihistamines (OR 1.53, 95% CI 1.43, 1.63).
Conclusions
Among ACEI users developing AE or ACEI intolerance, several comorbidities and comedication classes were significantly more prevalent compared with ACEI users not developing these adverse reactions.
DOI: 10.1111/bcp.13090
View this article